Progressive supranuclear palsy
Clinical research in progressive supranuclear palsy is centered on disease-modifying treatment development and long-term evaluation of motor and functional decline, with attention to neurological symptom progression and safety in adults living with this rare neurodegenerative disorder.
- PSP Rating Scale
- disease progression
- neurological function
The portfolio reflects interest in therapies aimed at slowing the clinical course of tau-related neurodegeneration and preserving daily functioning in people with PSP.
Amyotrophic lateral sclerosis
Research activity in amyotrophic lateral sclerosis focuses on treatment options for a progressive motor neuron disease, with emphasis on changes in functional status, symptom burden, and overall disease evolution in affected participants.
- motor neuron degeneration
- functional progression
- ALS therapy
This area highlights therapeutic interest in interventions intended to address the course of ALS and its impact on movement, strength, and independence.
Healthy volunteer studies
Studies in healthy volunteers support evaluation of pharmacokinetics, tolerability, and comparative product performance for orally administered treatments and fixed-dose combinations.
- bioequivalence
- fixed-dose combinations
- oral formulations
These investigations include comparative assessment of established cardiovascular and antiplatelet medicines in adult volunteers under controlled conditions.
Neurodegenerative disease therapeutics
The wider research landscape is concentrated on central nervous system disorders, especially conditions marked by progressive impairment of movement, coordination, and neurological performance.
- movement disorders
- clinical neurology
- symptom progression
Work in this domain supports therapeutic development for rare neurodegenerative diseases with unmet medical need.
